Neurocrine Biosciences (NBIX) Capital Leases (2010 - 2017)

Neurocrine Biosciences' Capital Leases history runs 8 years deep, the most recent figure standing at $544000.0 for Q1 2017.

• Quarterly Capital Leases fell 32.76% year-over-year to $544000.0 in Q1 2017, while the trailing twelve-month figure through Mar 2017 was $544000.0 (down 32.76% YoY) and the FY2016 annual result came in at $617000.0, down 60.32% from the prior year.
• Capital Leases was $544000.0 for Q1 2017 at Neurocrine Biosciences, down from $617000.0 in the prior quarter.
• Across five years, Capital Leases topped out at $3.0 million in Q1 2013 and bottomed at $544000.0 in Q1 2017.
• A 5-year average of $1.8 million and a median of $2.1 million in 2015 frame the typical range for Capital Leases.
• Annual changes were most pronounced in 2013 — Capital Leases soared 32.63% — and 2016, when it plunged 61.22%.
• Neurocrine Biosciences' Capital Leases stood at $2.7 million in 2013, then slipped by 17.5% to $2.2 million in 2014, then decreased by 29.67% to $1.6 million in 2015, then plunged by 60.32% to $617000.0 in 2016, then retreated by 11.83% to $544000.0 in 2017.
• Business Quant data shows NBIX's Capital Leases at $544000.0 in Q1 2017, $617000.0 in Q4 2016, and $649000.0 in Q3 2016.